Company Overview and News

Tops Of 35 'Safer' Dividend REITs, Select, Boasts 37% Net Gains Per Broker April Targets

2018-04-18 seekingalpha
Top net gain "safer" dividend Real Estate stocks NLY, TWO, VTR, DX, LAMR, MTGE, EARN, CHMI, IRS & SIR averaged 21.9% net 4/13/18. Six also were top yielders.
Upvote Downvote

AGNC Investment's Q1 2018 And 4/17/2018 BV Projection (Includes MTGE And NLY BV Projection)

2018-04-18 seekingalpha
I am projecting AGNC will report a modest decrease in quarterly BV for the first quarter of 2018. Most sector peers will also experience a BV decrease (especially fixed-rate agency).
Upvote Downvote

AGNC Investment's Q1 2018 Income Statement And Earnings Preview - Part 3 (Notable MBS Price Decreases)

2018-04-16 seekingalpha
I am projecting AGNC will report a combined notable net unrealized loss on available-for-sale securities and investment securities measured at FMV for the first quarter of 2018.
Upvote Downvote

MORL Is Attractive With 20.5% Yield And Possible Easing Of Risk Factors

2018-03-30 seekingalpha
While the risks regarding protectionism and Federal Reserve tightening to offset declining unemployment rates are substantial, there may be some mitigating factors.
Upvote Downvote

DX / Dynex Capital, Inc. DEF 14A

Upvote Downvote

DX / Dynex Capital, Inc. DEFA14A

Upvote Downvote

REML 21.9% Yield Could Compensate For Many Risks

2018-03-28 seekingalpha
There are some factors that many market participants may have overlooked regarding the major risks facing the financial markets.
Upvote Downvote

Orchid Island Capital And Cherry Hill Mortgage Investment: MBS Pricing For Q1 2018

2018-03-28 seekingalpha
Following continued requests by readers, this article analyzes fixed-rate agency MBS price movements during the first quarter of 2018 (through 3/23/2018).
Upvote Downvote

24 'Safer' Dividends Out Of My Readers 49 Most Mentioned Dividend Stocks For March

2018-03-25 seekingalpha
From 2/1-3/5/18, Fredrik Arnold dividend "followers" discussed 49 equities and funds in their messages and comments. Some comments were bad news, so bad rogues mixed into a FollowerFavorite/Rogue (FoFa/Ro) list.
Upvote Downvote

27 Russell 3000 'Safer' Dividend Stocks: A Bevy Of REITs For March

2018-03-20 seekingalpha
27 of 95 Russell 3000 Index stocks were deemed "safer" for dividends because they showed positive one-year returns and free cash flow yields greater than their dividend yields 3/15/18.
Upvote Downvote

BRIEF-Dynex Capital Says‍ Effective March 12 Amended Bylaws To Implement Majority Voting In Uncontested Elections Of Directors

2018-03-16 reuters
Upvote Downvote

Dividends Are Not New York Mortgage Trust's Primary Focus

2018-03-13 seekingalpha
This research report was jointly produced by The REIT Forum with assistance from Big Dog Investments.
Upvote Downvote

27 'Safer' Dividend REITs: Cherry Hill, IRSA, CYS, And Sutherland Are Tops As Per Broker's March Targets

2018-03-06 seekingalpha
Top net gain "safer" dividend Real Estate stocks averaged 20.48% net 3/3/18. Five also claimed top yields.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 26817Q506